<DOC>
	<DOCNO>NCT02830282</DOCNO>
	<brief_summary>This nested multicenter , prospective cohort study within I-SPY 2 TRIAL woman undergo neoadjuvant chemotherapy primary breast cancer also undergo definitive surgical resection clinical radiographic evidence residual tumor completion chemotherapy .</brief_summary>
	<brief_title>Surveillance Markers Utility Recurrence After Neoadjuvant Chemotherapy Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<criteria>Enrollment treatment phase ISPY 2 TRIAL Completed standard neoadjuvant chemotherapy regimen assign treatment ISPY 2 plan definitive surgical resection . Participants discontinue assigned treatment ISPY 2 , switch standard care , complete standard neoadjuvant chemotherapy regimen still consider eligible . Presurgical image clinical examination demonstrate residual disease breast . Participants extent enhancement attributable tumor presurgical MRI eligible . No minimum extent palpable tumor presurgery require . Willing undergo bone marrow aspiration blood specimen collection per protocol specification No clinical evidence distant metastatic disease . Prechemotherapy stag scan sufficient absence symptom subsequent clinical evidence suggest distant metastasis Age 18 able give inform consent Individuals age 18 Individuals understand give inform consent . We assess decisional capacity ; determination ability give inform consent discretion treat physician . Pregnancy . Participants parent ISPY 2 TRIAL screen pregnancy enrollment pregnancy exclusion criterion . No additional screening pregnancy require participant enrol SURMOUNT . However study participant become pregnant study course 10 year followup , study participant remain study protocol withdrawn . Because observational study therapeutic component , increase risk follow study participant annual blood draw medical information abstraction medical chart may may become pregnant course followup period .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>